Stocks Health care DWTX
NASDAQ · Health careDogwood Therapeutics, Inc. (DWTX)
It posted a net loss of $36M. At June 30, 2026 it held $9.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about Dogwood Therapeutics, Inc.
- Net worth
- Dogwood Therapeutics, Inc. has a market value (market cap) of $40.8M at the latest share price, and shareholders' equity of $68.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $15.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Dogwood Therapeutics, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
What Dogwood Therapeutics, Inc. does
Dogwood Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker DWTX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$34.3M | -$7.13 | n/a |
| 2024 | n/a | -$12.3M | -$12.52 | n/a |
| 2023 | n/a | -$5.3M | -$7.05 | n/a |
| 2022 | n/a | -$12.2M | -$27.95 | n/a |
| 2021 | n/a | -$16M | -$48.34 | n/a |
| 2021 | n/a | -$10.3M | -$52.88 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Dogwood Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 14, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026
- June 17, 2026
- May 15, 2026Passive stake (5% or more) SCHEDULE 13G
- May 15, 2026
- May 14, 2026
- April 27, 2026
- April 27, 2026Proxy statement DEF 14A
- April 17, 2026Preliminary proxy statement PRE 14A
Insider trades
What the people running Dogwood Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 21, 2025 | Sealbond LtdDirector, 10% owner | Exercised options | 21,610,950 | - |
| November 21, 2025 | Sealbond LtdDirector, 10% owner | Exercised optionsindirect | 2,842,638 | - |
Who owns DWTX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| CK Life Sciences Int'l., (Holdings) Inc.13D, may seek influence with 2 related filers | 83% | November 25, 2025 |
| Sealbond Limited13D, may seek influence with 1 related filers | 15.9% | October 15, 2024 |
| Armistice Capital, LLC13G, passive with 1 related filers | 9.99% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 15 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Armistice Capital, LLC | 3,132,486 | -147,514 |
| Millennium Management LLC | 341,814 | new |
| Vanguard Capital Management LLC | 132,154 | 0 |
| Geode Capital Management, LLC | 88,298 | +8,864 |
| Vanguard Fiduciary Trust Co | 62,736 | 0 |
| BlackRock, Inc. | 28,546 | +28,516 |
| Northern Trust Corp | 23,779 | 0 |
| Citadel Advisors LLC | 11,742 | new |
| Tower Research Capital LLC (TRC) | 3,093 | -4,974 |
| Morgan Stanley | 2,222 | new |
| UBS Group AG | 1,860 | -5,225 |
| Jones Financial Companies Lllp | 160 | new |
| Barclays PLC | 157 | new |
| Activest Wealth Management | 120 | 0 |
| Group One Trading LLC | 9 | 0 |
Insiders
1 insiders reported holding 24,664,971 shares in total, about $29.6M at the last price.
| Holder | Shares |
|---|---|
| Sealbond LtdDirector, 10% owner | 24,664,9712,842,638 held indirectly |
Questions about DWTX
What does Dogwood Therapeutics, Inc. do?
Dogwood Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as DWTX. Its shares trade on NASDAQ under the ticker DWTX.
What is Dogwood Therapeutics, Inc.'s net worth?
Dogwood Therapeutics, Inc. has a market value (market cap) of $40.8M at the latest share price, and shareholders' equity of $68.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Dogwood Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $36M.
When did Dogwood Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026.
When is Dogwood Therapeutics, Inc.'s next earnings report?
Dogwood Therapeutics, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
Similar companies
Compare DWTX with
Follow DWTX
Get an email when Dogwood Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Dogwood Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.